Akoya Biosciences, Inc. (NASDAQ:AKYA), known as The Spatial Biology Company®, operates in the Zacks Medical - Biomedical and Genetics industry. The company focuses on spatial biology solutions, which are used in life science research. Despite challenges in the life science tools market, Akoya has made strides in improving its financial health and expanding its market presence.
On March 17, 2025, Akoya reported an earnings per share (EPS) of -$0.16, slightly missing the estimated EPS of -$0.15. This represents a 13.33% negative surprise, as highlighted by Zacks. However, it is an improvement from the previous year's loss of $0.22 per share. In the previous quarter, Akoya reported a loss of $0.18 per share, better than the expected $0.19, resulting in a positive surprise of 5.26%.
Akoya's revenue for the quarter was $21.34 million, marginally surpassing the estimated revenue. However, it fell short of the Zacks Consensus Estimate by 1.05% and marked a decline from the $26.49 million reported in the same quarter the previous year. Over the past four quarters, Akoya has consistently failed to meet consensus revenue estimates, indicating ongoing challenges in revenue generation.
Despite these challenges, Akoya has made significant progress in its operations. The company improved its gross margins and reduced operating expenses, as highlighted by its CEO, Brian McKelligon. Akoya expanded its installed base to 1,330 instruments and launched a Manufacturing Center of Excellence to enhance gross margins. The company also ventured into new markets like neurobiology and advanced its clinical partnerships.
Financially, Akoya's metrics reflect its current challenges. The company has a negative price-to-earnings (P/E) ratio of -1.40, indicating a lack of profitability. However, its price-to-sales ratio of 0.95 and enterprise value to sales ratio of 0.90 suggest a relatively low valuation compared to its sales. Akoya's debt-to-equity ratio of 1.05 indicates moderate debt usage, while a current ratio of 2.61 shows strong liquidity, enabling it to cover short-term liabilities effectively.
